Phoenix-based Insys Therapeutics Inc. recently revealed that its new branded liquid formulation Syndros (dronabinol oral solution) is on the market to address side effects of AIDS and chemotherapy such as weight loss and related symptoms.
“The launch of Syndros represents a pivotal milestone for us,” INSYS President and CEO Saeed Motahari said. “Syndros is the second product entirely developed and commercialized by INSYS. We are excited to make Syndros available to those patients in need and look forward to bringing additional novel therapeutic solutions to even more patients in the near future.”
Insys SVP for regulatory affairs Stephen Sherman added that the product is the first and only liquid dronabinol to gain FDA approval, stating that it “will fulfill a significant unmet need for both cancer patients undergoing chemotherapy who fail traditional antiemetics and AIDS patients who experience weight loss.”
Dronabinol is a pharmaceutical cannabinoid; Syndros is indicated both in patients with anorexia and weight loss resulting from AIDS and in those experiencing chemotherapy-induced nausea and vomiting.
The company noted that over 15 million U.S. patients have cancer diagnoses; of the side effects produced by chemotherapy, nausea and vomiting are among the most severe. Additionally, 1.2 million individuals have received a diagnosis of AIDS since the early 1980s; approximately 7 to 8 percent of those patients experience weight loss.